开启建立在免疫发病机制上的儿童免疫性血小板减少症诊疗新时代

摘要

With advances in medical sciences,immune thrombocytopenia (ITP) is gradually regarded as one of diseases characterized bv underlying loss of immune tolerance.Accordingly,treatment methods and strategy are shifting from traditional clinical experience to targeted therapy on a step-by-step basis.As for chronic and refractory ITP,combination therapy,novel immunological targeting drugs are turning out to be more effective treatment options.With further understanding of ITP pathogenesis,the elucidation of infections in the development of childhood ITP,the realization that ITP is in fact an immunological syndrome,and the distinction of other diseases with ITP-like clinical manifestations,are of great clinical implications.%随着医疗科学的发展,儿童免疫性血小板减少症(immune thrombocytopenia,ITP)被逐步认为是一种免疫失耐受疾病,治疗手段与策略也从传统临床经验性治疗逐步转变成为建立在免疫机制上的靶向治疗,而针对慢性/难治性ITP,联合治疗、免疫靶向新药治疗将为更有效的治疗提供多种选择.同时,随着ITP机制的研究更深入了解,感染在儿童ITP发病机制中起到一定的作用,如何理解ITP是一种免疫综合征以及对类似ITP表现的其他疾病的准确筛选有重要意义.